Clinical Trial Update: A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture. [Phase 4]

View source ↗

Summary

Phase 4 study of romosozumab (EVENITY) in postmenopausal women with osteoporosis at high fracture risk in India has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postmenopausal Osteoporosis

Drugs mentioned

• Evenity (romosozumab)

Snippet

Sponsor: Amgen | Conditions: Postmenopausal Osteoporosis | Phase 4 | Status: COMPLETED